Catarina Costa Sousa

Dr. Catarina Costa Sousa

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2019 in Cancers
Verified
Journal Article
Open access
PDF file
MFmaria gabriela fernandes
maria gabriela fernandes
MJMaria Jacob
Maria Jacob
Natália Cruz-MartinsNatália Cruz-Martins
Natália Cruz-Martins
CMConceição Souto Moura
Conceição Souto Moura
SGSusana Guimarães
Susana Guimarães
JCJosé Luis Costa
José Luis Costa
Identification of targetable molecular changes is essential for selecting appropriate treatment in patients with advanced lung adenocarcinoma. Methods: In this study, a Sanger sequencing plus Fluorescence In Situ Hybridization (FISH) sequential approach was compared with a Next-Generation Sequencing (NGS)-based approach for the detection of actionable genomic mutations in an experimental cohort (EC) of 117 patients with advanced lung adenocarcinoma. Its applicability was assessed in small biopsies and cytology specimens previously tested for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutational status, comparing the molecular changes identified and the impact on clinical outcomes. Subsequently, an NGS-based approach was applied and tested in an implementation cohort (IC) in clinical practice. Using Sanger and FISH, patients were classified as EGFR-mutated (n = 22, 18.8%), ALK-mutated (n = 9, 7.7%), and unclassifiable (UC) (n = 86, 73.5%). Retesting the EC with NGS led to the identification of at least one gene variant in 56 (47.9%) patients, totaling 68 variants among all samples. Still, in the EC, combining NGS plus FISH for ALK, patients were classified as 23 (19.7%) EGFR; 20 (17.1%) KRAS; five (4.3%) B-Raf proto-oncogene (BRAF); one (0.9%) Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2); one (0.9%) STK11; one (0.9%) TP53, and nine (7.7%) ALK mutated. Only 57 (48.7%) remained genomically UC, reducing the UC rate by 24.8%. Fourteen (12.0%) patients presented synchronous alterations. Concordance between NGS and Sanger for EGFR status was very high (κ = 0.972; 99.1%). In the IC, a combined DNA and RNA NGS panel was used in 123 patients. Genomic variants were found in 79 (64.2%). In addition, eight (6.3%) EML4-ALK, four (3.1%), KIF5B-RET, four (3.1%) CD74-ROS1, one (0.8%) TPM3-NTRK translocations and three (2.4%) exon 14 skipping MET Proto-Oncogene (MET) mutations were detected, and 36% were treatable alterations. Conclusions: This study supports the use of NGS as the first-line test for genomic profiling of patients with advanced lung adenocarcinoma.

28 July 2021 in Cells
Verified
Journal Article
Open access
PDF file
MFmaria gabriela fernandes
maria gabriela fernandes
CSCatarina Costa Sousa
Catarina Costa Sousa
JRJoana Pereira Reis
Joana Pereira Reis
Natália Cruz-MartinsNatália Cruz-Martins
Natália Cruz-Martins
CMConceição Souto Moura
Conceição Souto Moura
VHVenceslau Hespanhol
Venceslau Hespanhol
Introduction: Cell-free DNA (cfDNA) analysis offers a non-invasive method to identify sensitising and resistance mutations in advanced Non-Small Cell Lung Cancer (NSCLC) patients. Next-generation sequencing (NGS) of circulating free DNA (cfDNA) is a valuable tool for mutations detection and disease′s clonal monitoring. Material and methods: An amplicon-based targeted gene NGS panel was used to analyse 101 plasma samples of advanced non-small cell lung cancer (NSCLC) patients with known oncogenic mutations, mostly EGFR mutations, serially collected at different clinically relevant time points of the disease. Results: The variant allelic frequency (VAF) monitoring in consecutive plasma samples demonstrated different molecular response and progression patterns. The decrease in or the clearance of the mutant alleles was associated with response and the increase in or the emergence of novel alterations with progression. At the best response, the median VAF was 0% (0.0% to 3.62%), lower than that at baseline, with a median of 0.53% (0.0% to 9.9%) (p = 0.004). At progression, the VAF was significantly higher (median 4.67; range: 0.0–36.9%) than that observed at the best response (p = 0.001) and baseline (p = 0.006). These variations anticipated radiographic changes in most cases, with a median time of 0.86 months. Overall, the VAF evolution of different oncogenic mutations predicts clinical outcomes. Conclusion: The targeted NGS of circulating tumour DNA (ctDNA) has clinical utility to monitor treatment response in patients with advanced lung adenocarcinoma.

3 June 2025 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
PFPedro Magalhães Ferreira1
Pedro Magalhães Ferreira1
RCRui Campos2
Rui Campos2
CVCarolina Valente1
Carolina Valente1
JFJoana Ferreira1
Joana Ferreira1
CFCláudia Freitas
Cláudia Freitas
2F2 Maria Gabriela O. Fernandes1
2 Maria Gabriela O. Fernandes1
Objectives: The 9th edition of the Tumor, Node, Metastasis (TNM-9) lung cancer classification is set to replace the 8th edition (TNM-8) starting in 2025. Key updates include the splitting of the mediastinal nodal category N2 into single- and multiple-station involvement, as well as the classification of multiple extrathoracic metastatic lesions as involving a single organ system (M1c1) or multiple organ systems (M1c2). This study aimed to assess how the TNM-9 revisions affect the final staging of lung cancer patients and how these changes correlate with overall survival (OS). Methods: This retrospective cohort study included patients diagnosed with lung cancer between 2018 and 2021, who were staged according to both TNM-8 and TNM-9 criteria. The staging classifications were analyzed and compared in relation to OS. Results: Among a total of 914 patients, 42 were re-staged using TNM-9. Of the 382 patients classified as stage IVB, 55.9% were reclassified as M1c2. Despite an absolute increase in mean OS for patients re-staged from IIB to IIA and from IIIA to IIB, the observed differences were not statistically significant. Median OS differed significantly both within stage IVB and between patients with M1c2 disease and other stage IV subgroups. Multi-organ metastatic disease was an independent predictor of poorer OS, regardless of age, sex, performance status, and oncologic treatment. Conclusions: TNM-9 improves prognostic accuracy in lung cancer. Although patients with multiple extrathoracic metastases involving different organ systems are not yet independently staged from IVB, they demonstrated significantly poorer OS compared to other advanced-stage patients.

24 February 2025 in Monaldi Archives for Chest Disease
Verified
Journal Article
Open access
PDF file
PFPedro Magalhães Ferreira
Pedro Magalhães Ferreira
JFJoana Ferreira
Joana Ferreira
CFCláudia Freitas
Cláudia Freitas
CSCatarina Costa Sousa
Catarina Costa Sousa
DADavid Araújo
David Araújo
MFMaria Gabriela Fernandes
Maria Gabriela Fernandes
Venous thromboembolism (VTE) is highly prevalent in cancer patients. While its actual incidence remains disparate among studies, specific subpopulations, such as lung cancer patients, might be at an increased risk. We aimed to assess the impact of a screening protocol in determining both the incidence and risk factors for VTE and evaluate the usefulness of predictive biomarkers and risk stratification tools in lung cancer patients. For this purpose, we designed a prospective cohort study including all consecutive, newly diagnosed lung cancer patients between October 2023 and April 2024 in a tertiary center and assessed each patient using a standardized screening protocol. VTE screening included baseline and 3-month reassessment of coagulation tests, D-dimer levels, and imaging (duplex ultrasound of the lower limbs for deep vein thrombosis screening and contrast-enhanced thoracic computed tomography for pulmonary embolism screening). A total of 102 patients were included, of which 16 (15.7%) were diagnosed with VTE. VTE was more frequent in males (p=0.031), patients with COPD (p=0.004), and patients with metastatic disease (p=0.038), particularly those under immunotherapy (p=0.026). Patients with VTE presented a D-dimer concentration more than three times higher at baseline and fivefold the levels observed in non-VTE patients at 3 months (p=0.002). Paired with Khorana scores, D-dimer concentration 4.5 mg/L at 3 months improved the predictive capacity of this VTE risk assessment tool in patients under active treatment. Active VTE screening yielded a significant increase in diagnosis, suggesting the incidence of this complication in newly diagnosed lung cancer patients is underestimated. Risk assessment tools can be enhanced by the addition of D-dimer-based parameters.

1 June 2021 in Archivos de Bronconeumología
Verified
Journal Article
Closed access
CSCatarina Costa Sousa
Catarina Costa Sousa
CDCarla Damas
Carla Damas

28 September 2019 in European Respiratory Journal
Verified
Conference Paper
Closed access
CSCatarina Costa Sousa
Catarina Costa Sousa
JPJosué Pinto
Josué Pinto
NMNatália Martins
Natália Martins
STSofia Teixeira
Sofia Teixeira
AMAdriana Magalhães
Adriana Magalhães
HBHelder Novais Bastos
Helder Novais Bastos
Introduction: KRAS comprise the most frequently found oncogene driver mutation in non-small cell lung cancer (NSCLC), accounting for 20-25% of these patients. KRAS mutant NSCLC has been associated with poorer survival, and no targeted therapy is currently approved. This study aimed to characterize the KRAS mutant NSCLC. Methods: A retrospective analysis of NSCLC patients, who performed next generation sequence (NGS) was carried out. KRAS mutant NSCLC demographic and clinical characteristics were reviewed. Results: Of 127 patients included, 27.6% had KRAS mutation (mean age 65.8±8.5 years). Patients with KRAS mutation were more likely to be males (80%, p=0.014) and smokers (88.6%, p=0.001). Thirty KRAS mutations were located in codon 12 (Gly12Cys, n=12; Gly12Val, n=9; Gly12Asp, n=7; Gly12Ala, n=2), 2 in codon 13 (Gly13Asp and Gly13Cys), 2 in codon 61 (Gln61His and Gln61Arg) and 1 in codon 60 (Gly60Asp). The most frequent metastatic sites were lung (42.9%) and bone (40%). KRAS-mutated group metastasize less to pleura compared with non-mutated group (11.4% vs 31.9%, p=0.030). Although mostly stage IV at the diagnosis (82.8%), KRAS-mutated group presented a better performance status (PS) compared to non-mutated group (PS 0-1 94.3% vs. 63.8%, p=0.001). Mean progression-free survival (PFS) in KRAS-mutated group tended to be shorter than in non-mutated group (3.6 vs. 4.2 months, p=0.658), as was the overall survival (OS) (7.1 vs 7.6 months, p=0.726). Conclusion: KRAS mutant NSCLC are more frequent in smoking male patients. Although KRAS-mutated group had a better PS at diagnosis, had a lower OS/PFS when compared with KRAS non-mutated group, which suggest that these patients present an aggressive disease.